MRI Method Predicts Early Response

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

NEW ORLEANS-Diffusion-weighted MRI reveals rapid changes in tumor water diffusion values after successful therapeutic intervention in solid tumors. It therefore appears capable of predicting treatment response within days of initiating therapy, Brian D. Ross, PhD, of the University of Michigan, said at the 92nd Annual Meeting of the American Association for Cancer Research (AACR).

NEW ORLEANS—Diffusion-weighted MRI reveals rapid changes in tumor water diffusion values after successful therapeutic intervention in solid tumors. It therefore appears capable of predicting treatment response within days of initiating therapy, Brian D. Ross, PhD, of the University of Michigan, said at the 92nd Annual Meeting of the American Association for Cancer Research (AACR).

Diffusion-weighted MRI yields information by testing the integrity of tumor cell membranes. The system tracks the ease with which water travels microscopic distances. The unbroken outer membranes of normal cells slow the movement of the water molecules, but "punctured" membranes around dead or dying cells allow water to diffuse more freely.

The diffusion-weighted MRI follows the random motion of water in the body, and yields a number that describes changes in tumor water diffusion values, Dr. Ross explained at a press conference.

Dr. Ross and his colleagues, including Thomas L. Chenevert, MD, who presented the findings, evaluated the method in rodents and have also obtained preliminary results in 12 primary brain tumor patients.

One patient, a 13-year-old female, had less than 20% tumor shrinkage after 8 weeks of therapy, which corresponded with a small increase in the diffusion coefficient of the tumor. "In this case, we could detect what we think is very small cell kill, even though it is not a significant therapeutic effect. In a clinical trial, this might indicate that a dose escalation or different route of administration should be tried," Dr. Ross said.

A second patient in the series had no regression of tumor, which correlated well with the total lack of change in diffusion, he reported. Outcomes are pending on other patients. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content